Evidence map›Paper›PMID 38963803›Full record

ReviewGenetics2024

Radio-miRs: a comprehensive view of radioresistance-related microRNAs.

Abraham Pedroza-Torres, Sandra L Romero-Córdoba, Sarita Montaño, Oscar Peralta-Zaragoza, Dora Emma Vélez-Uriza, Cristian Arriaga-Canon, Xiadani Guajardo-Barreto, Diana Bautista-Sánchez, Rodrigo Sosa-León, Olivia Hernández-González and 3 more

Abstract readReview
In one paragraph

Review in Genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abraham Pedroza-TorresPrograma Investigadoras e Investigadores por México, Consejo Nacional de Humanidades, Ciencias y Tecnologías, Mexico City C.P. 03940, Mexico.ORCID 0000-0001-7857-3464
Sandra L Romero-CórdobaDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City C.P. 04510, Mexico.ORCID 0000-0002-5591-696X
Sarita MontañoLaboratorio de Bioinformática, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa (FCQB-UAS), Culiacán Rosales, Sinaloa C.P. 80030, Mexico.ORCID 0000-0002-0420-4268
Oscar Peralta-ZaragozaDirección de Infecciones Crónicas y Cáncer, Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos C.P. 62100, Mexico.
Dora Emma Vélez-UrizaLaboratorio de Traducción y Cáncer, Instituto Nacional de Cancerología, Mexico City C.P. 14080, Mexico.
Cristian Arriaga-CanonUnidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas-Universidad Nacional Autónoma de México (UNAM), Mexico City C.P. 14080, Mexico.ORCID 0000-0002-4866-9067
Xiadani Guajardo-BarretoUnidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas-Universidad Nacional Autónoma de México (UNAM), Mexico City C.P. 14080, Mexico.
Diana Bautista-SánchezDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Rodrigo Sosa-LeónClínica de Cáncer Hereditario, Instituto Nacional de Cancerología, Mexico City C.P. 14080, Mexico.
Olivia Hernández-GonzálezLaboratorio de Microscopia Electrónica, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarraa Ibarra", Mexico City C.P. 14389, Mexico.ORCID 0000-0003-1343-4732
José Díaz-ChávezUnidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas-Universidad Nacional Autónoma de México (UNAM), Mexico City C.P. 14080, Mexico.
Rosa María Alvarez-GómezClínica de Cáncer Hereditario, Instituto Nacional de Cancerología, Mexico City C.P. 14080, Mexico.
Luis A HerreraUnidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas-Universidad Nacional Autónoma de México (UNAM), Mexico City C.P. 14080, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy is a key treatment option for a wide variety of human tumors, employed either alone or alongside with other therapeutic interventions. Radiotherapy uses high-energy particles to destroy tumor cells, blocking their ability to divide and proliferate. The effectiveness of radiotherapy is due to genetic and epigenetic factors that determine how tumor cells respond to ionizing radiation. These factors contribute to the establishment of resistance to radiotherapy, which increases the risk of poor clinical prognosis of patients. Although the mechanisms by which tumor cells induce radioresistance are unclear, evidence points out several contributing factors including the overexpression of DNA repair systems, increased levels of reactive oxygen species, alterations in the tumor microenvironment, and enrichment of cancer stem cell populations. In this context, dysregulation of microRNAs or miRNAs, critical regulators of gene expression, may influence how tumors respond to radiation. There is increasing evidence that miRNAs may act as sensitizers or enhancers of radioresistance, regulating key processes such as the DNA damage response and the cell death signaling pathway. Furthermore, expression and activity of miRNAs have shown informative value in overcoming radiotherapy and long-term radiotoxicity, revealing their potential as biomarkers. In this review, we will discuss the molecular mechanisms associated with the response to radiotherapy and highlight the central role of miRNAs in regulating the molecular mechanisms responsible for cellular radioresistance. We will also review radio-miRs, radiotherapy-related miRNAs, either as sensitizers or enhancers of radioresistance that hold promise as biomarkers or pharmacological targets to sensitize radioresistant cells.

Indexed as

MicroRNAsNeoplasmsRadiation ToleranceAnimalsDNA DamageDNA RepairGene Expression Regulation, NeoplasticHumansMicroRNAsionizing radiationmicroRNAsradio-miRsradioresistanceradiotherapy

Identifiers

PMID38963803
PMCPMC11304977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.